Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Down 86.8% in April

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) saw a large decrease in short interest during the month of April. As of April 30th, there was short interest totaling 169 shares, a decrease of 86.8% from the April 15th total of 1,276 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 5,628 shares, the short-interest ratio is currently 0.0 days.

Institutional Trading of Invesco Biotechnology & Genome ETF

A number of hedge funds and other institutional investors have recently made changes to their positions in PBE. Colonial Trust Advisors acquired a new stake in shares of Invesco Biotechnology & Genome ETF during the 4th quarter worth approximately $25,000. Fifth Third Bancorp acquired a new stake in shares of Invesco Biotechnology & Genome ETF during the 1st quarter worth approximately $30,000. Comerica Bank increased its holdings in shares of Invesco Biotechnology & Genome ETF by 86.2% during the 4th quarter. Comerica Bank now owns 378 shares of the company’s stock worth $31,000 after buying an additional 175 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Invesco Biotechnology & Genome ETF by 74.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock worth $40,000 after buying an additional 245 shares during the last quarter. Finally, NewEdge Advisors LLC increased its holdings in shares of Invesco Biotechnology & Genome ETF by 63.2% during the 3rd quarter. NewEdge Advisors LLC now owns 883 shares of the company’s stock worth $62,000 after buying an additional 342 shares during the last quarter.

Invesco Biotechnology & Genome ETF Trading Up 0.6%

PBE stock traded up $0.46 during mid-day trading on Tuesday, reaching $82.99. The company’s stock had a trading volume of 4,231 shares, compared to its average volume of 6,860. The stock has a market cap of $258.10 million, a PE ratio of 20.44 and a beta of 0.71. Invesco Biotechnology & Genome ETF has a fifty-two week low of $59.75 and a fifty-two week high of $85.73. The company’s 50 day moving average is $79.31 and its two-hundred day moving average is $80.19.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.